AstraZeneca: ALXN1840 Met Primary Endpoint in Phase 3 Trial for Wilson Disease
26 Agosto 2021 - 03:34AM
Dow Jones News
By Ian Walker
AstraZeneca PLC said Thursday that ALXN1840 met the primary
endpoint in a FoCus Phase 3 trial for Wilson disease, showing an
improvement in copper mobilization from tissues.
The pharmaceutical giant said that ALXN1840 demonstrated about
three times more copper mobilization from tissues than
standard-of-care treatments.
Wilson disease is a rare and progressive genetic condition in
which the body's pathway for removing excess copper is
compromised.
Separately AstraZeneca said that Forxiga has been approved in
Japan for the treatment of chronic kidney disease in patients with
and without type-2 diabetes.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
August 26, 2021 02:32 ET (06:32 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
AstraZeneca (NASDAQ:AZN)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024